Table 3.
Clinical outcomes in patients between the tirofiban and control groups.
| Tirofiban, % | Control, % | OR | 95% CI | P | |
|---|---|---|---|---|---|
| Restenosis | 2 | 6.1 | 0.319 | 0.063–1.623 | 0.279 |
| Bleeding | 10.2 | 7.1 | 1.477 | 0.538–4.053 | 0.613 |
| 3–5 Times normal | 3.1 | 11.2 | 0.250 | 0.067–0.925 | 0.027* |
| 5 Upper times normal | 3.1 | 5.1 | 0.587 | 0.136–2.528 | 0.721 |
| Abnormal Q wave | 13.3 | 12.2 | 1.096 | 0.473–2.539 | 1 |
| Left atrial (> 40 mm) | 35.7 | 51 | 0.533 | 0.301–0.945 | 0.031* |
| LVEF (< 50%) | 30.6 | 24.5 | 1.36 | 0.725–2.553 | 0.337 |
OR, odds ratio; CI, confidence interval; LVEF, left ventricular ejection fraction
*P < 0.05.